DermTech’s total covered lives in the U.S. are now approximately 115 million.

Two new payers plan to cover the DermTech Melanoma Test, making the foundational assay available to approximately 1.2 million more people.

The new insurers are Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. The coverage policies are similar to the Medicare coverage policy of the Company’s foundational assay included in the DermTech Melanoma Test.

“We are eager to work with these commercial payers to bring our test to their membership,” says Dan Visage, senior vice president of payor access, DermTech, in a news release. “The DMT test results are clinically meaningful and actionable, improve patient care and reduce healthcare costs. After reviewing our portfolio of clinical and health economic data, payers are increasingly acknowledging the value of our test and resulting benefits to their membership, network providers and health plans.”

DermTech’s total covered lives in the U.S. are now approximately 115 million, which includes 68 million for Medicare/Medicare Advantage and 47 million for commercial and governmental payers, the company reports.